OHR Pharmaceutical (NASDAQ:OHRP) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07), Bloomberg Earnings reports.
Shares of OHR Pharmaceutical (NASDAQ:OHRP) opened at $0.27 on Friday. OHR Pharmaceutical has a twelve month low of $0.26 and a twelve month high of $2.18. The stock has a market cap of $15.08, a price-to-earnings ratio of -0.45 and a beta of -0.30.
Several analysts have recently commented on the stock. Zacks Investment Research raised shares of OHR Pharmaceutical from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a report on Wednesday, October 25th. ValuEngine downgraded shares of OHR Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Friday, January 5th. Finally, Roth Capital downgraded shares of OHR Pharmaceutical from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a report on Friday, January 5th.
A hedge fund recently raised its stake in OHR Pharmaceutical stock. Vanguard Group Inc. increased its position in shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) by 0.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 812,418 shares of the biotechnology company’s stock after buying an additional 5,481 shares during the period. Vanguard Group Inc. owned 1.45% of OHR Pharmaceutical worth $520,000 as of its most recent filing with the SEC. 8.32% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/17/ohr-pharmaceutical-ohrp-posts-quarterly-earnings-results-hits-expectations.html.
About OHR Pharmaceutical
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.